While blood-based tests are readily available for various conditions, including
cardiovascular diseases, type 2 diabetes, and common cancers, Alzheimer's disease (AD) …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by
cognitive decline, memory loss, and impaired daily functioning. The pathology of AD is …

Introduction Diagnosis of dementia in the aging brain is confounded by the presence of
multiple pathologies. Mixed dementia (MX), a combination of Alzheimer's disease (AD) …

Background PET imaging of the translocator protein (TSPO) is used to assess in vivo brain
inflammation. One of the main methodological issues with this method is the allelic …

Background Many groups have been using immunomagnetic reduction (IMR) for assaying
plasma amyloid-β 1-40 (Aβ1-40) peptide, Aβ1-42 peptide and total tau protein (T-Tau) in …

INTRODUCTION Alzheimer's disease (AD) is increasing in the Caribbean, especially for
persons of African ancestry (PAA) and women. However, studies have mostly utilized …

Background Plasma amyloid-β (Aβ), phosphorylated tau-181 (p-tau181), neurofilament light
(NfL) and glial fibrillary acidic protein (GFAP) potentially aid in the diagnosis of …

Aim To assess the association between plasma amyloid β (Aβ) 42/40, phosphorylated tau (p‐
τ) 181, glial fibrillary acidic protein (GFAP), or neurofilament light chain (NfL) and the risk of …

Background: We investigated systemic biochemical changes in Alzheimer's disease (AD) by
investigating the relationship between circulating plasma metabolites and both clinical and …

Background We profiled circulating plasma metabolites to identify systemic biochemical
changes in clinical and biomarker-assisted diagnosis of Alzheimer's disease (AD). Methods …